Inotuzumab ozogamicin: Difference between revisions
Jump to navigation
Jump to search
m Protected "Inotuzumab ozogamicin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 33: | Line 33: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:25, 9 August 2012
Overview
Inotuzumab ozogamicin is a humanized monoclonal antibody and which is used to treat cancers. Inotuzumab has a chelator, ozogamicin, same as in gemtuzumab.